The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300 · cited 1×
“One mechanism could involve AMPK, which acts as a general regulator of energy expenditure (Cantó et al., 2009); also, SGLTs are functionally expressed in rat brain (Yu et al., 2010), and the possibility that SGLTi may cross the blood-brain barrier and act in brain regions governing appetite and…”
BackgroundExplaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 2×
“…in cardiovascular disease (CVD) mortality in the Western Hemisphere (Ford et al., 2007), a 2-fold gradient in CVD incidence persists between patients with type 2 (Emerging Risk Factors Collaboration et al., 2011) or type 1 diabetes (Lind et al., 2014) and the respective background populations.”
BackgroundThe theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580
Self-citationBiology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 7×
“The improved b cell function documented in studies in patients with type 2 diabetes is most likely the result of the reduced glycemic burden (Ferrannini et al., 2014; DeFronzo et al., 2017; Polidori et al., 2014).”
BackgroundInfluentialSelf-citationThe effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.
DeFronzo, R. A., Cooke, C. R., Andres, R., Faloona, G. R., & Davis, P. J. (1975) · Journal of Clinical Investigation · doi:10.1172/jci107996 · Cited by 1,115
Interplay between lipids and branched-chain amino acids in development of insulin resistance
Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.01.024 · Cited by 1,080 · cited 1×
“Branched-chain amino acids, a signature of insulin resistance (Newgard, 2012) and diabetes (Ferrannini et al., 2013), might also be affected, either directly (e.g., via urinary excretion) or indirectly (through the improved insulin sensitivity).”
BackgroundEffect of fatty acids on glucose production and utilization in man.
Ferrannini, E., Barrett, E. J., Bevilacqua, S., & DeFronzo, R. A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111133 · Cited by 1,050
Self-citationCV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Self-citationGlycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964 · cited 1×
“…in cardiovascular disease (CVD) mortality in the Western Hemisphere (Ford et al., 2007), a 2-fold gradient in CVD incidence persists between patients with type 2 (Emerging Risk Factors Collaboration et al., 2011) or type 1 diabetes (Lind et al., 2014) and the respective background populations.”
BackgroundDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Hostetter, T. H., Rennke, H. G., & Brenner, B. M. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90490-9 · Cited by 796
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 777
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Self-citationTestani, J. M., Chen, J., McCauley, B. D., Kimmel, S. E., & Shannon, R. P. (2010) · Circulation · doi:10.1161/circulationaha.109.933275 · Cited by 680
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 1×
“The latter response presumably is due to loosening of the inhibition of a cell activity by intraislet insulin (Maruyama et al., 1984); this paracrine effect may be seconded by direct inhibition of glucose entry into a cells through SGLT2 (Bonner et al., 2015).”
BackgroundRosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664
Self-citationVallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635 · cited 2×
“In rodent diabetes, empagliflozin reduces renal growth (Vallon et al., 2014); whether this effect is present in humans is not known (Vallon and Thomson, 2017).”
BackgroundGerich, J. E. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02894.x · Cited by 633
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Vallon, V., Platt, K. A., Cunard, R., Schroth, J., Whaley, J., Thomson, S. C., Koepsell, H., & Rieg, T. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010030246 · Cited by 563
SGLT2 Inhibitors May Predispose to Ketoacidosis
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1884 · Cited by 560
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Renal Autoregulation in Health and Disease
Carlström, M., Wilcox, C. S., & Arendshorst, W. J. (2015) · Physiological Reviews · doi:10.1152/physrev.00042.2012 · Cited by 485
Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458
Self-citationThe effects of glucose and insulin on renal electrolyte transport.
DeFronzo, R. A., Goldberg, M., & Agus, Z. S. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108463 · Cited by 456
Insulin, ketone bodies, and mitochondrial energy transduction
Sato, K., Kashiwaya, Y., Keon, C. A., Tsuchiya, N., King, M. T., Radda, G. K., Chance, B., Clarke, K., & Veech, R. L. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768357 · Cited by 454
Kidney dimensions at sonography: correlation with age, sex, and habitus in 665 adult volunteers.
Emamian, S. A., Nielsen, M. B., Pedersen, J. F., & Ytte, L. (1993) · American Journal of Roentgenology · doi:10.2214/ajr.160.1.8416654 · Cited by 454
Effect of insulin on uric acid excretion in humans
Quinones Galvan, A., Natali, A., Baldi, S., Frascerra, S., Sanna, G., Ciociaro, D., & Ferrannini, E. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.268.1.e1 · Cited by 451
Self-citationSGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 398
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Chino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., & Tamai, I. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1909 · Cited by 389
Glucose handling by the kidney
Mather, A., & Pollock, C. (2011) · Kidney International · doi:10.1038/ki.2010.509 · Cited by 375
Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
Self-citationFerrannini, E., Natali, A., Camastra, S., Nannipieri, M., Mari, A., Adam, K.-P., Milburn, M. V., Kastenmüller, G., Adamski, J., Tuomi, T., et al. (2013) · Diabetes · doi:10.2337/db12-0707 · Cited by 349
Self-citationHalestrap, A. P. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c130008 · Cited by 339
Mäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314
Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D. R., Thomson, S. C., Koepsell, H., & Vallon, V. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00518.2013 · Cited by 310
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
Wang, X. X., Levi, J., Luo, Y., Myakala, K., Herman-Edelstein, M., Qiu, L., Wang, D., Peng, Y., Grenz, A., Lucia, S., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.779520 · Cited by 306
Insulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“Thus, whether and to what extent renal gluconeogenesis contributes to augment EGP has not been determined (Gerich, 2010; Mather and Pollock, 2011).”
BackgroundGlucose transport families SLC5 and SLC50
Wright, E. M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.11.002 · Cited by 301
Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., Shalayda, K., Demarest, K., & Rothenberg, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01406.x · Cited by 297
DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293
Nephron mass as a risk factor for progression of renal disease.
Brenner, B. M., & Mackenzie, H. S. (1997) · PubMed · Cited by 287
Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications
Sas, K. M., Kayampilly, P., Byun, J., Nair, V., Hinder, L. M., Hur, J., Zhang, H., Lin, C., Qi, N. R., Michailidis, G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86976 · Cited by 268
Polidori, D., Sha, S., Mudaliar, S., Ciaraldi, T. P., Ghosh, A., Vaccaro, N., Farrell, K., Rothenberg, P., & Henry, R. R. (2013) · Diabetes Care · doi:10.2337/dc12-2391 · Cited by 261
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Self-citationZambrowicz, B., Freiman, J., Brown, P. M., Frazier, K. S., Turnage, A., Bronner, J., Ruff, D., Shadoan, M., Banks, P., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 243
Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., Du, F., Liu, Y., Xu, J., Conway, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030555 · Cited by 240
Perkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., Fagan, N. M., Kaspers, S., Woerle, H.-J., Broedl, U. C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2338 · Cited by 231
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R. (2015) · Diabetes Care · doi:10.2337/dc15-0642 · Cited by 225
Mogensen, C. E. (1971) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517109090668 · Cited by 221
Demonstration of a day-night rhythm in human skeletal muscle oxidative capacity
van Moorsel, D., Hansen, J., Havekes, B., Scheer, F. A. J. L., Jörgensen, J. A., Hoeks, J., Schrauwen-Hinderling, V. B., Duez, H., Lefebvre, P., Schaper, N. C., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.012 · Cited by 218
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Daniele, G., Xiong, J., Solis-Herrera, C., Merovci, A., Eldor, R., Tripathy, D., DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2016) · Diabetes Care · doi:10.2337/dc15-2688 · Cited by 213
Devenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212
Vestri, S., Okamoto, M. M., de Freitas, H. S., Aparecida dos Santos, R., Nunes, M. T., Morimatsu, M., Heimann, J. C., & Machado, U. F. (2001) · Journal of Membrane Biology · doi:10.1007/s00232-001-0036-y · Cited by 191
EFFECT OF DIABETES AND INSULIN ON THE MAXIMUM CAPACITY OF THE RENAL TUBULES TO REABSORB GLUCOSE 1
Farber, S. J., Berger, E. Y., & Earle, D. P. (1951) · Journal of Clinical Investigation · doi:10.1172/jci102424 · Cited by 185
Pathophysiology and clinical evaluation of acute heart failure
Mentz, R. J., & O'Connor, C. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.134 · Cited by 184
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Barsotti, E., Clerico, A., & Muscelli, E. (2017) · Diabetes Care · doi:10.2337/dc16-2724 · Cited by 181
Self-citationCherney, D., Lund, S. S., Perkins, B. A., Groop, P.-H., Cooper, M. E., Kaspers, S., Pfarr, E., Woerle, H. J., & von Eynatten, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4008-2 · Cited by 174
Surprising Versatility of Na+-Glucose Cotransporters: SLC5
Wright, E. M., Loo, D. D. F., Hirayama, B. A., & Turk, E. (2004) · Physiology · doi:10.1152/physiol.00026.2004 · Cited by 171
Marks, J., Carvou, N. J. C., Debnam, E. S., Srai, S. K., & Unwin, R. J. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.046268 · Cited by 166
Balen, D., Ljubojević, M., Breljak, D., Brzica, H., Z̆lender, V., Koepsell, H., & Sabolić, I. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00180.2008 · Cited by 166
Renal oxygenation and haemodynamics in acute kidney injury and chronic kidney disease
Singh, P., Ricksten, S., Bragadottir, G., Redfors, B., & Nordquist, L. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12036 · Cited by 157
Shyangdan, D., Uthman, O. A., & Waugh, N. R. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009417 · Cited by 153
THE ACTION OF PHLORIZIN ON THE EXCRETION OF GLUCOSE, XYLOSE, SUCROSE, CREATININE AND UREA BY MAN
Chasis, H., Jolliffe, N., & Smith, H. W. (1933) · Journal of Clinical Investigation · doi:10.1172/jci100559 · Cited by 152
Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes
Tiwari, S., Riazi, S., & ECELBARGER, C. A. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00149.2007 · Cited by 138
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
Lapuerta, P., Zambrowicz, B., Strumph, P., & Sands, A. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114563304 · Cited by 134
Regulation of the human Na+-dependent glucose cotransporter hSGLT2
Ghezzi, C., & Wright, E. M. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00115.2012 · Cited by 125
Briand, F., Mayoux, E., Brousseau, E., Burr, N., Urbain, I., Costard, C., Mark, M., & Sulpice, T. (2016) · Diabetes · doi:10.2337/db16-0049 · Cited by 124
Functional expression of SGLTs in rat brain
Yu, A. S., Hirayama, B. A., Timbol, G., Liu, J., Basarah, E., Kepe, V., Satyamurthy, N., Huang, S., Wright, E. M., & Barrio, J. R. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00296.2010 · Cited by 123
Metabolic Effects of Low-Dose Insulin Therapy on Glucose Metabolism in Diabetic Ketoacidosis
Luzi, L., Barrett, E. J., Groop, L., Ferrannini, E., & DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.11.1470 · Cited by 120
Self-citationProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea
Bankir, L., Roussel, R., & Bouby, N. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00614.2014 · Cited by 118
Polidori, D., Mari, A., & Ferrannini, E. (2014) · Diabetologia · doi:10.1007/s00125-014-3196-x · Cited by 117
Self-citationImpaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients
Christensen, P. K., Hansen, H. P., & Parving, H. (1997) · Kidney International · doi:10.1038/ki.1997.463 · Cited by 117
Dobbins, R. L., Greenway, F. L., Chen, L., Liu, Y., Breed, S. L., Andrews, S. M., Wald, J. A., Walker, A. C., & Smith, C. D. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00286.2014 · Cited by 114
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Xiao, F., Zimpelmann, J., Woerle, H., Johansen, O. E., Broedl, U. C., von Eynatten, M., & Burns, K. D. (2014) · Kidney International · doi:10.1038/ki.2014.246 · Cited by 113
Central Role of Sodium in Hypertension in Diabetic Subjects
Weidmann, P. U., & Ferrari, P. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.220 · Cited by 105
Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine
Elsas, L. J., & Rosenberg, L. E. (1969) · Journal of Clinical Investigation · doi:10.1172/jci106150 · Cited by 101
Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice
Sala‐Rabanal, M., Hirayama, B. A., Ghezzi, C., Liu, J., Huang, S., Kepe, V., Koepsell, H., Yu, A. S., Powell, D. R., Thorens, B., et al. (2016) · The Journal of Physiology · doi:10.1113/jp271904 · Cited by 97
Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback
Woods, L. L., Mizelle, H. L., & Hall, J. E. (1987) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1987.252.1.f65 · Cited by 96
Heise, T., Jordan, J., Wanner, C., Heer, M. A., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., & Broedl, U. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.001 · Cited by 96
Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats.
Kamran, M., Peterson, R. G., & Dominguez, J. H. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v86943 · Cited by 84
EMPA-REG – the “diuretic hypothesis”
McMurray, J. J. V. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.012 · Cited by 83
Sodium‐glucose co‐transporter ( SGLT )2 and SGLT1 renal expression in patients with type 2 diabetes
Solini, A., Rossi, C., Mazzanti, C. M., Proietti, A., Koepsell, H., & Ferrannini, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12970 · Cited by 83
Self-citationChin, E., Zamah, A. M., Landau, D., Grønbæk, H., Flyvbjerg, A., LeRoith, D., & Bondy, C. A. (1997) · Endocrinology · doi:10.1210/endo.138.3.5015 · Cited by 81
Daniele, G., Eldor, R., Merovci, A., Clarke, G. D., Xiong, J., Tripathy, D., Taranova, A. G., Abdul-Ghani, M. A., & DeFronzo, R. A. (2013) · Diabetes · doi:10.2337/db13-1130 · Cited by 81
on behalf of the RISC Investigators, Ferrannini, E., Natali, A., Muscelli, E., Nilsson, P. M., Golay, A., Laakso, M., Beck-Nielsen, H., & Mari, A. (2011) · Diabetologia · doi:10.1007/s00125-011-2112-x · Cited by 80
Self-citationInsulin Resistance in Diabetic Ketoacidosis
Barrett, E. J., DeFronzo, R. A., Bevilacqua, S., & Ferrannini, E. (1982) · Diabetes · doi:10.2337/diab.31.10.923 · Cited by 80
Self-citationUnderstanding EMPA-REG OUTCOME
Muskiet, M. H. A., van Raalte, D. H., van Bommel, E. J. M., Smits, M. M., & Tonneijck, L. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00424-6 · Cited by 79
Yabe, D., Iwasaki, M., Kuwata, H., Haraguchi, T., Hamamoto, Y., Kurose, T., Sumita, K., Yamazato, H., Kanada, S., & Seino, Y. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12848 · Cited by 69
Okauchi, S., Shimoda, M., Obata, A., Kimura, T., Hirukawa, H., Kohara, K., Mune, T., Kaku, K., & Kaneto, H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.109 · Cited by 64
A Renal Olfactory Receptor Aids in Kidney Glucose Handling
Shepard, B. D., Cheval, L., Peterlin, Z. A., Firestein, S., Koepsell, H., Doucet, A., & Pluznick, J. L. (2016) · Scientific Reports · doi:10.1038/srep35215 · Cited by 62
Sabolić, I., Škarica, M., Gorboulev, V., Ljubojević, M., Balen, D., Herak-Kramberger, C. M., & Koepsell, H. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00270.2005 · Cited by 49
Merovci, A., Abdul‐Ghani, M. A., Mari, A., Solis‐Herrera, C., Xiong, J., Daniele, G., Tripathy, D., & DeFronzo, R. A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2597 · Cited by 48
Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies
Christensen, P. K., Hommel, E. E., Clausen, P., Feldt‐Rasmussen, B., & Parving, H. H. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00676.x · Cited by 47
The EMPA-REG study: What has it told us? A diabetologist’s perspective
DeFronzo, R. A. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.013 · Cited by 41
Bell, T. D., DiBona, G. F., Wang, Y., & Brands, M. W. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006030216 · Cited by 39
Ottosson-Laakso, E., Tuomilehto, J., Forsén, B., Gullström, M., Groop, P., Groop, L., & Vikman, P. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146114 · Cited by 39
Jensen, M. L., Persson, F., Andersen, G. S., Ridderstråle, M., Nolan, J. J., Carstensen, B., & Jørgensen, M. E. (2017) · Diabetes Care · doi:10.2337/dc16-2793 · Cited by 37
Christensen, S. L. P. K. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510151067965 · Cited by 29
Muscelli, E., Astiarraga, B., Barsotti, E., Mari, A., Schliess, F., Nosek, L., Heise, T., Broedl, U. C., Woerle, H., & Ferrannini, E. (2015) · Diabetologia · doi:10.1007/s00125-015-3845-8 · Cited by 25
Self-citationQiu, R., Balis, D. A., Capuano, G. A., Xie, J., & Meininger, G. E. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0201-z · Cited by 10
Cherney, D., Cooper, M. E., Tikkanen, I., Crowe, S., Johansen, O. E., Lund, S. S., Woerle, H. J., Broedl, U. C., & Hach, T. (2015) · Journal of Hypertension · doi:10.1097/01.hjh.0000467485.28062.c1 · Cited by 7
Cited by
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms
Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.005 · Cited by 1,787
“SGLT2 inhibitors promote lowering of the threshold for urinary glucose excretion: an additional glucose equivalent to 300 kcal per day is therefore cleared by the kidneys, promoting weight loss and a catabolic state with increased circulating ketone bodies and NEFAs.(106) There are associated reductions in BP and plas…”
BackgroundAhmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Kim, S. R., Lee, S.-G., Kim, S. H., Kim, J. H., Choi, E., Cho, W., Rim, J. H., Hwang, I., Lee, C. J., Lee, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15983-6 · Cited by 536
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
Metadata
- Authors
- Ferrannini, E.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 26
- Issue
- 1
- Pages
- 27-38
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2613261853
- Cited by
- 340
- References
- 113
- FWCI
- 21.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.